Courses of individual patients
| Patient . | EBV-related disease, other . | Maximum dose/MTD, mg/kg . | No. cycles . | Outcome, 1 cycle . | Prior therapies/chemotherapy regimens . | Adverse events . |
|---|---|---|---|---|---|---|
| 1 | PTLD; s/p lung transplant | 500/500 | < 1, 15 d | CR | CHOP × 6 | Confusion; diarrhea; emesis-coffee ground; rejection of transplanted lung* |
| 2 | DLBCL (CNS); s/p BMT × 2 for AML, GVHD | 1800/1800 | < 1, 16 d | CR | ACV, IL-2, IgG, dexamethasone; XRT (brain) (2 regimens) | Confusion; mucositis; headache; N/V; abdominal pain |
| 3 | PTLD; s/p BMT/PBSC transplant for AML, GVHD | 2000/2000 | < 1, 19 d | PR | IDA/ARA-C; mitoxantrone | Confusion; N/V; tumor lysis leading to bowel perforation* |
| 4 | Anaplastic DLBCL; s/p HIV | 2000/2000 | 1 | PR | Vinblastine, anthracyclines, AraC; cisplatinum, Steroids | Confusion; N/V; anorexia |
| 5 | DLBCL (paranasal) | 2000/2000 | 1 | NR | XRT, CHOP × 6; MTX, doxorubicin, vincristine (3 regimens) | Confusion; restlessness; somnolence; N/V, abdominal pain; visual changes; orthostasis |
| 6 | PTLD, s/p renal transplant | 1000/1000 | 1 | NR | BMT, CHOP × 2 | Headache; N/V; abd. pain thrombocytopenia |
| 7 | Extranodal T-cell lymphoma | 2000/1500 | 1 | CR | CHOP × 3, XRT | Lethargy/stupor/confusion; hypotonia/hypoesthesia; fungal infection/mucositis; tumor lysis leading to hemorrhage* |
| 8 | Extranodal NK/T-cell lymphoma | 1500/1000 | 1 | PR | XRT, APO × 2, cytoxan, MTX × 2; cisplatinum/AraC/VP-16; (4 regimens) | Acoustic hallucinations; somnolence; hypokalemia; sepsis, DVT |
| 9 | Extranodal NK/T-cell lymphoma | 2000/2000 | 1 | CR | ACVBP, DHAP, ICE, MTX, dexamethasone (4 regimens) | Confusion; fatigue; elevated BUN; tumor lysis leading to pancreatitis/hepatitis* |
| 10 | PTLD; s/p lung transplant | 1000/800 | 1 | NR | None | Elevated BUN; encephalopathy |
| 11 | PTLD; s/p BMT and SCT, GVHD | 1500/1500 | < 1, 8 d | PR | VCR/prednisone, L-Asp; Daunorubicin, IT MTX, AraC, cytoxan, 6-MP/MTX (2 regimens) | Diarrhea; hepatomegaly |
| 12 | Hodgkin: 1 nodule EBV+, mediastinal mass EBV− | 2000/2000 | 1 | NR | MOPP, ABVD, DHAP, CCNU; VP-16, cytoxan XRT, BMT (6 regimens) | Nausea; pneumonia; port infection |
| 13 | Subcutaneous panniculitis-like T-cell lymphoma; pulmonary metastases | 938/938 | 3 | PR | Hyper-CVAD × 3; ICE, VP-I6, anti-CD3 Ab; HuM291; denileukin diftitox × 3 (5 regimens) | Nausea, anorexia, weight loss; anemia; thrombocytopenia; lethargy; insomnia; hypokalemia |
| 14 | Extranodal NK/T-cell lymphoma | 1250/1250 | < 1, 19 d | NR | CHOP × 4; ESHAP, ICE × 3-(3 regimens), XRT | Sinus, throat, back pain; thrombocytopenia; hypokalemia; lethargy |
| 15 | DLBCL | 1000/1000 | < 1, 5 d | PR | CHOP × 6 | Lethargy; increased dyspnea; polymicrobial pneumonia/ARDS |
| Patient . | EBV-related disease, other . | Maximum dose/MTD, mg/kg . | No. cycles . | Outcome, 1 cycle . | Prior therapies/chemotherapy regimens . | Adverse events . |
|---|---|---|---|---|---|---|
| 1 | PTLD; s/p lung transplant | 500/500 | < 1, 15 d | CR | CHOP × 6 | Confusion; diarrhea; emesis-coffee ground; rejection of transplanted lung* |
| 2 | DLBCL (CNS); s/p BMT × 2 for AML, GVHD | 1800/1800 | < 1, 16 d | CR | ACV, IL-2, IgG, dexamethasone; XRT (brain) (2 regimens) | Confusion; mucositis; headache; N/V; abdominal pain |
| 3 | PTLD; s/p BMT/PBSC transplant for AML, GVHD | 2000/2000 | < 1, 19 d | PR | IDA/ARA-C; mitoxantrone | Confusion; N/V; tumor lysis leading to bowel perforation* |
| 4 | Anaplastic DLBCL; s/p HIV | 2000/2000 | 1 | PR | Vinblastine, anthracyclines, AraC; cisplatinum, Steroids | Confusion; N/V; anorexia |
| 5 | DLBCL (paranasal) | 2000/2000 | 1 | NR | XRT, CHOP × 6; MTX, doxorubicin, vincristine (3 regimens) | Confusion; restlessness; somnolence; N/V, abdominal pain; visual changes; orthostasis |
| 6 | PTLD, s/p renal transplant | 1000/1000 | 1 | NR | BMT, CHOP × 2 | Headache; N/V; abd. pain thrombocytopenia |
| 7 | Extranodal T-cell lymphoma | 2000/1500 | 1 | CR | CHOP × 3, XRT | Lethargy/stupor/confusion; hypotonia/hypoesthesia; fungal infection/mucositis; tumor lysis leading to hemorrhage* |
| 8 | Extranodal NK/T-cell lymphoma | 1500/1000 | 1 | PR | XRT, APO × 2, cytoxan, MTX × 2; cisplatinum/AraC/VP-16; (4 regimens) | Acoustic hallucinations; somnolence; hypokalemia; sepsis, DVT |
| 9 | Extranodal NK/T-cell lymphoma | 2000/2000 | 1 | CR | ACVBP, DHAP, ICE, MTX, dexamethasone (4 regimens) | Confusion; fatigue; elevated BUN; tumor lysis leading to pancreatitis/hepatitis* |
| 10 | PTLD; s/p lung transplant | 1000/800 | 1 | NR | None | Elevated BUN; encephalopathy |
| 11 | PTLD; s/p BMT and SCT, GVHD | 1500/1500 | < 1, 8 d | PR | VCR/prednisone, L-Asp; Daunorubicin, IT MTX, AraC, cytoxan, 6-MP/MTX (2 regimens) | Diarrhea; hepatomegaly |
| 12 | Hodgkin: 1 nodule EBV+, mediastinal mass EBV− | 2000/2000 | 1 | NR | MOPP, ABVD, DHAP, CCNU; VP-16, cytoxan XRT, BMT (6 regimens) | Nausea; pneumonia; port infection |
| 13 | Subcutaneous panniculitis-like T-cell lymphoma; pulmonary metastases | 938/938 | 3 | PR | Hyper-CVAD × 3; ICE, VP-I6, anti-CD3 Ab; HuM291; denileukin diftitox × 3 (5 regimens) | Nausea, anorexia, weight loss; anemia; thrombocytopenia; lethargy; insomnia; hypokalemia |
| 14 | Extranodal NK/T-cell lymphoma | 1250/1250 | < 1, 19 d | NR | CHOP × 4; ESHAP, ICE × 3-(3 regimens), XRT | Sinus, throat, back pain; thrombocytopenia; hypokalemia; lethargy |
| 15 | DLBCL | 1000/1000 | < 1, 5 d | PR | CHOP × 6 | Lethargy; increased dyspnea; polymicrobial pneumonia/ARDS |
DLBCL indicates diffuse large B cell lymphoma; s/p, status post; BMT, bone marrow transplant; GVHD, graft-versus-host disease; PBSC, peripheral blood stem cell; SCT, stem cell transplant; EBV, Epstein Barr virus; MTD, maximum tolerated dose; NR, no response; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; IL-2, interleukin 2; IgG, immunoglobulin G; XRT, radiotherapy; AraC, cytarabine; MTX, methotrexate; APO, vincristine, adriamycin, and prednisone; VP-16, etoposide; ACVBP doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; ICE, ifosfamide, carboplatin, and etoposide; VCR, vincristine; IT, intrathecal; 6-MP, 6-mercaptopurine; MOPP, mechlorethamine, vincristine, prednisone, and procarbazine; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; CCNU, lomustine; CVAD, cyclophosphamide, vincristine, adriamycin, and dexamethasone; HuM291, visilizumab; ICE, ifosfamide-carboplatin-etoposide; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; and N/V, nausea/vomiting.
*Fatal adverse event.